BGB-16673 is moving through the Pipeline - CLL Support
BGB-16673 is moving through the Pipeline
You need to be a member of this community to see this post.
Read more about...
9 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
Zanubrutinib-Gazyva Shows Promise for CLL/SLL
June 25, 2019
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BTK Degrader Shows Potential for Treating Refractory CLL and SLL
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients...
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in
Related Posts
- Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD- Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
- BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
- Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
